Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)
| Docket | ⤷ Sign Up | Date Filed | 2024-01-09 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 15:1125 Trademark Infringement (Lanham Act) | Assigned To | Jennifer L. Hall |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 10,149,829; 9,539,234; 9,730,910 | ||
| Link to Docket | External link to docket | ||
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-01-29 | 1 | 11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…drug sponsor submits “the patent number and the expiration date of any patent which claims the drug … or…manufacturer’s patent rights. Instead, an ANDA applicant must certify “with respect to each patent which claims…seeking approval” that “such patent information has not been filed,” “such patent has expired,” “the date | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
